Vera Therapeutics (NASDAQ:VERA) Releases Earnings Results, Misses Estimates By $0.06 EPS

Vera Therapeutics (NASDAQ:VERA - Get Free Report) announced its earnings results on Thursday. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06), Zacks reports. During the same quarter in the prior year, the firm posted ($0.56) earnings per share.

Vera Therapeutics Price Performance

Shares of VERA traded down $0.26 during trading hours on Friday, hitting $21.77. The stock had a trading volume of 1,262,456 shares, compared to its average volume of 779,548. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -8.34 and a beta of 1.28. Vera Therapeutics has a 52 week low of $18.53 and a 52 week high of $51.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The company's fifty day moving average is $24.22 and its two-hundred day moving average is $34.72.

Analyst Upgrades and Downgrades

VERA has been the subject of several research analyst reports. JPMorgan Chase & Co. dropped their price objective on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research note on Tuesday, March 4th. Wolfe Research began coverage on Vera Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price objective for the company. The Goldman Sachs Group started coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $58.00 price target for the company. HC Wainwright initiated coverage on shares of Vera Therapeutics in a research report on Monday, May 5th. They set a "buy" rating and a $75.00 price target for the company. Finally, Wedbush cut their price objective on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Vera Therapeutics presently has a consensus rating of "Buy" and an average price target of $63.80.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.